<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The catastrophic anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> syndrome (CAPS) differs from the anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> syndrome in its accelerated systemic involvement leading to multi-organic failure </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, the occurrence of <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> in patients with CAPS was evaluated and the clinical findings of CAPS patients with and without <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> were compared </plain></SENT>
<SENT sid="2" pm="."><plain>We investigated the web site-based international registry of patients with CAPS for <z:hpo ids='HP_0000001'>all</z:hpo> cases in which both CAPS and underlying <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> were present </plain></SENT>
<SENT sid="3" pm="."><plain>The clinical characteristics of these cases were subsequently evaluated to establish common characteristics </plain></SENT>
<SENT sid="4" pm="."><plain>The CAPS registry included information on a total of 262 cases </plain></SENT>
<SENT sid="5" pm="."><plain>Twenty-three (9%) patients suffered from <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>In 78% of these patients, the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> itself or the treatment modalities instituted for the <z:mp ids='MP_0002038'>carcinoma</z:mp> was the precipitating factor of CAPS </plain></SENT>
<SENT sid="7" pm="."><plain>Only 39% of CAPS patients with <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> recovered in comparison to 58% of patients without <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> (p = 0.07) </plain></SENT>
<SENT sid="8" pm="."><plain>Treatment modalities, however, did not differ significantly between these patients </plain></SENT>
<SENT sid="9" pm="."><plain><z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">Infections</z:e> were not evident as precipitating factors for any of the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> patients </plain></SENT>
<SENT sid="10" pm="."><plain>The mean age of patients with <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> was 9 years older than the average age of other patients with CAPS and the prevalence of SLE was significantly less common than in patients without <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Malignancy</z:e> may play a pathogenic role in patients with CAPS, whereas <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> are more important as triggering factors in patients without <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>CAPS patients with <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> are generally older than CAPS patients without <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>; they generally have the worst prognosis of the entire CAPS cohort </plain></SENT>
</text></document>